#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	13572	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2152	627.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1456	1456	C	804	C,T	751,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24618	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	677.1	0	.	n	.	0	T695C	SNP	695	695	T	1025	1025	C	697	C	652	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24618	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	677.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1667	1667	A	823	A,G	778,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24618	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	677.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2301	2301	C	813	C	761	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24618	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	677.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2375	2375	A	781	A	740	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24618	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3625	677.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2927	2927	C	769	C	717	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1896	folP	852	852	100.0	folP.l15.c17.ctg.1	1614	116.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1122	1124	AGC	206;206;206	A;G;C	196;200;197	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4898	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3498	139.7	1	SNP	p	S91F	0	.	.	271	273	TCC	632	634	TCC	149;150;151	T;C;C	141;142;144	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4898	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3498	139.7	1	SNP	p	D95N	0	.	.	283	285	GAC	644	646	GAC	153;156;155	G;A;C	141;143;145	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4898	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3498	139.7	1	SNP	p	D95G	0	.	.	283	285	GAC	644	646	GAC	153;156;155	G;A;C	141;143;145	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1430	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1254	113.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	466	468	ACC	163;160;161	A,G;C;C	148,1;153;155	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1430	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1254	113.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	481	483	CAC	162;162;161	C;A;C	154;150;152	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1430	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1254	113.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	664	666	CAC	170;168;168	C;A;C	162;159;159	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1430	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1254	113.1	1	SNP	p	G45D	0	.	.	133	135	GGC	484	486	GGC	162;161;162	G;G;C	150;154;156	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	724	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	961	74.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4902	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2920	167.2	1	SNP	p	D86N	0	.	.	256	258	GAC	531	533	GAC	193;191;191	G,A;A;C	180,1;178;180	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4902	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2920	167.2	1	SNP	p	S87W	0	.	.	259	261	AGT	534	536	AGT	189;189;189	A;G;T	178;180;178	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4902	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2920	167.2	1	SNP	p	S87I	0	.	.	259	261	AGT	534	536	AGT	189;189;189	A;G;T	178;180;178	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4902	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2920	167.2	1	SNP	p	S87R	0	.	.	259	261	AGT	534	536	AGT	189;189;189	A;G;T	178;180;178	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4902	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2920	167.2	1	SNP	p	S88P	0	.	.	262	264	TCC	537	539	TCC	187;195;194	T;C;C	177;183;184	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4122	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2657	154.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1536	1538	GGC	210;208;207	G;G;C	198;195;192	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1302	1304	GCA	215;216;214	G,A;C;A	194,1;195;196	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1305	1307	ATC	212;211;211	A;T;C	195;194;195	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1317	1319	GTG	202;200;201	G;T;G	189;183;185	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1317	1319	GTG	202;200;201	G;T;G	189;183;185	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1821	1823	ACC	184;186;186	A;C;C	167;174;178	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1875	1877	GCG	185;186;187	G;C;G	163;152;159	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1875	1877	GCG	185;186;187	G;C;G	163;152;159	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1998	2000	GGC	154;154;154	G;G;C	141;142;142	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2007	2009	GGC	147;146;145	G;G;C	132;131;131	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2428	149.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2025	2027	CCG	128;129;133	C,G;C,G;G	96,2;90,1;101	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	116	96.55	penA.l15.c4.ctg.2	116	0.0	0	.	p	.	0	V490G	NONSYN	1468	1470	GTG	72	74	GGG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	116	96.55	penA.l15.c4.ctg.2	116	0.0	0	.	p	.	0	D491G	NONSYN	1471	1473	GAC	75	77	GGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	116	96.55	penA.l15.c4.ctg.2	116	0.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	54	56	ACC	ND;ND;ND	ND;ND;ND	ND;ND;ND	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	116	96.55	penA.l15.c4.ctg.2	116	0.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	108	110	GCG	ND;ND;ND	ND;ND;ND	ND;ND;ND	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	527	3648	penA	1749	116	96.55	penA.l15.c4.ctg.2	116	0.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	108	110	GCG	ND;ND;ND	ND;ND;ND	ND;ND;ND	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5340	ponA	2397	2397	99.21	ponA.l6.c17.ctg.1	3308	161.1	0	.	p	.	0	F13V	NONSYN	37	39	TTT	484	486	GTT	196;198;197	G,T;T;T	183,1;186;185	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5340	ponA	2397	2397	99.21	ponA.l6.c17.ctg.1	3308	161.1	0	.	p	.	0	R257Q	NONSYN	769	771	CGG	1216	1218	CAG	234;232;231	C,T;A,G;G	221,1;216,4;220	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5340	ponA	2397	2397	99.21	ponA.l6.c17.ctg.1	3308	161.1	0	.	p	.	0	R272Q	NONSYN	814	816	CGG	1261	1263	CAG	207;210;211	C;A,G;G	199;199,2;204	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5340	ponA	2397	2397	99.21	ponA.l6.c17.ctg.1	3308	161.1	0	.	p	.	0	T295A	NONSYN	883	885	ACC	1330	1332	GCT	219;220;224	G,A;C;T,C	201,3;205;207,2	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5340	ponA	2397	2397	99.21	ponA.l6.c17.ctg.1	3308	161.1	0	.	p	.	0	A300V	NONSYN	898	900	GCG	1345	1347	GTG	225;225;227	G;T,C;G	211;203,2;209	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5340	ponA	2397	2397	99.21	ponA.l6.c17.ctg.1	3308	161.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1708	1710	CTG	163;165;165	C;T;G	151;150;151	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2184	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1834	118.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	616	616	C	142	C	131	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	314	90.88	porB1a.l15.c17.ctg.1	1210	20.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	921	923	AAT	15;14;14	A;A;T	15;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	314	90.88	porB1a.l15.c17.ctg.1	1210	20.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	924	926	AAT	14;14;14	A;A;T	14;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	314	90.88	porB1a.l15.c17.ctg.1	1210	20.7	0	.	p	.	0	A222V	NONSYN	664	666	GCT	936	938	GTT	13;13;12	G;T;T	13;13;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	314	90.88	porB1a.l15.c17.ctg.1	1210	20.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	948	950	GCA	11;11;11	G;C;A	11;11;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	314	90.88	porB1a.l15.c17.ctg.1	1210	20.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	971	973	GTA	13;13;13	G;T;A	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	314	90.88	porB1a.l15.c17.ctg.1	1210	20.7	0	.	p	.	0	D238fs	FSHIFT	712	712	G	983	983	G	15	G	15	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2492	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1500	165.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	446	448	GGA	207;205;208	G;G;A	191;187;189	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2492	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1500	165.5	0	.	p	.	0	F135L	NONSYN	403	405	TTT	707	709	CTT	213;215;215	C;T;T	201;203;203	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2492	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1500	165.5	0	.	p	.	0	R143G	NONSYN	427	429	AGA	731	733	GGA	216;214;214	G,T;G;A	199,1;199;199	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2492	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1500	165.5	0	.	p	.	0	D171G	NONSYN	511	513	GAT	815	817	GGT	193;195;199	G;G;T	180;185;182	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2492	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1500	165.5	0	.	p	.	0	G189S	NONSYN	565	567	GGC	869	871	AGC	185;184;183	A;G;C	176;175;174	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2492	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1500	165.5	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	935	935	T	150	T	146	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2492	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1500	165.5	1	SNP	p	G120K	0	.	.	358	360	GGT	662	664	GGT	202;199;200	G;G;T	197;192;190	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2492	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1500	165.5	1	SNP	p	A121D	0	.	.	361	363	GCC	665	667	GCC	197;200;201	G;C;C	190;193;194	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2492	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1500	165.5	1	SNP	p	A121N	0	.	.	361	363	GCC	665	667	GCC	197;200;201	G;C;C	190;193;194	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9508	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4963	191.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2099	2101	AAT	243;244;244	A;A;T	229;229;230	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1060	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1064	99.0	1	SNP	p	V57M	1	.	.	169	171	ATG	556	558	ATG	224;222;220	A;T,A;G,A	213;208,1;209,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
